DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Darvocet-N (Propoxyphene Napsylate / Acetaminophen) - Summary

 



BOX WARNING

WARNINGS

  • Do not prescribe propoxyphene for patients who are suicidal or addiction-prone.
  • Prescribe propoxyphene with caution for patients taking tranquilizers or antidepressant drugs and patients who use alcohol in excess.
  • Tell your patients not to exceed the recommended dose and to limit their intake of alcohol.

Propoxyphene products in excessive doses, either alone or in combination with other CNS depressants, including alcohol, are a major cause of drug-related deaths. Fatalities within the first hour of overdosage are not uncommon. In a survey of deaths due to overdosage conducted in 1975, in approximately 20% of the fatal cases, death occurred within the first hour (5% occurred within 15 minutes). Propoxyphene should not be taken in doses higher than those recommended by the physician. The judicious prescribing of propoxyphene is essential to the safe use of this drug. With patients who are depressed or suicidal, consideration should be given to the use of non-narcotic analgesics. Patients should be cautioned about the concomitant use of propoxyphene products and alcohol because of potentially serious CNS-additive effects of these agents. Because of its added depressant effects, propoxyphene should be prescribed with caution for those patients whose medical condition requires the concomitant administration of sedatives, tranquilizers, muscle relaxants, antidepressants, or other CNS-depressant drugs. Patients should be advised of the additive depressant effects of these combinations.

Many of the propoxyphene-related deaths have occurred in patients with previous histories of emotional disturbances or suicidal ideation or attempts as well as histories of misuse of tranquilizers, alcohol, and other CNS-active drugs. Some deaths have occurred as a consequence of the accidental ingestion of excessive quantities of propoxyphene alone or in combination with other drugs. Patients taking propoxyphene should be warned not to exceed the dosage recommended by the physician.

 

DARVOCET-N SUMMARY

DARVOCET-N® 50
and
DARVOCET-N® 100
PROPOXYPHENE NAPSYLATE
AND ACETAMINOPHEN
TABLETS, USP

Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is (α S,1 R) - α-[2-(Dimethylamino)-1-methylethyl]-α-phenylphenethyl propionate compound with 2-naphthalenesulfonic acid (1:1) monohydrate, which can be represented by the accompanying structural formula. Its molecular weight is 565.74.

Propoxyphene napsylate differs from propoxyphene hydrochloride in that it allows more stable liquid dosage forms and tablet formulations. Because of differences in molecular weight, a dose of 100 mg (176.8 μmol) of propoxyphene napsylate is required to supply an amount of propoxyphene equivalent to that present in 65 mg (172.9 μmol) of propoxyphene hydrochloride.

Each tablet of Darvocet-N® 50 contains 50 mg (88.4 μmol) propoxyphene napsylate and 325 mg (2,150 μmol) acetaminophen.

Each tablet of Darvocet-N® 100 contains 100 mg (176.8 μmol) propoxyphene napsylate and 650 mg (4,300 μmol) acetaminophen.

These products are indicated for the relief of mild to moderate pain, either when pain is present alone or when it is accompanied by fever.


See all indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Darvocet-N (Propoxyphene / Acetaminophen)

propoxyphene and acetaminophen, Darvocet A500; Darvocet-N (Darvocet, Wygesic)
Source: MedicineNet Tylenol Liver Damage Specialty [2009.09.10]
Title: propoxyphene and acetaminophen, Darvocet A500; Darvocet-N (Darvocet, Wygesic)
Category: Medications
Created: 3/26/1998 2:30:00 PM
Last Editorial Review: 9/10/2009

Yoga May Be Effective For Chronic Low Back Pain In Minority Populations
Source: Health News from Medical News Today [2009.11.05]
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center found that yoga may be more effective than standard treatment for reducing chronic low back pain in minority populations. This study appears in the November issue of Alternative Therapies in Health and Medicine.


Radiation Therapy Technique Successfully Treats Pain In Patients With Advanced Cancer
Source: Cancer / Oncology News From Medical News Today [2009.11.05]
Stereotactic radiosurgery (SRS), a radiation therapy procedure pioneered at the University of Pittsburgh Cancer Institute (UPCI) that precisely delivers a large dose of radiation to tumors, effectively controls pain in patients with cancer that has spread to the spine, according to researchers from UPCI. The results of the research were presented this week during the American Society for Radiation Oncology (ASTRO) annual meeting in Chicago, being held November 1 - 5, 2009.

Common Pain Relievers May Dilute Power Of Flu Shots
Source: Biology / Biochemistry News From Medical News Today [2009.11.04]
With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers -- Advil, Tylenol, aspirin -- at the time of injection may blunt the effect of the shot and have a negative effect on the immune system. Richard P. Phipps, Ph.D.

Cancer, Pain Relief And Immunity Research Supported By ARC
Source: Breast Cancer News From Medical News Today [2009.11.04]
Research at the Walter and Eliza Hall Institute into the genes involved in breast cancer development, new drugs for chronic pain, and the proteins involved in inflammatory diseases has received funding in this year's round of Australian Research Council (ARC) Discovery Project grants. Seven projects proposed by institute researchers have received ARC support.

more news >>

Published Studies Related to Darvocet-N (Propoxyphene / Acetaminophen)

Acceptability and efficacy of two associations of paracetamol with a central analgesic (dextropropoxyphene or codeine): comparison in osteoarthritis. [1992.11]
A double-blind randomized parallel group trial was undertaken to compare the acceptability and efficacy of 2 forms of analgesic treatment, DI-Antalvic (Houde Laboratories, Puteaux, France) (30 mg dextropropoxyphene and 400 mg paracetamol per capsule) and Efferalgan-Codeine (UPSA Laboratories, Rueil Malmaison, France) (30 mg codeine and 500 mg paracetamol per tablet) prescribed for 1 week at doses of 6 capsules/day and 6 tablets/day, respectively, in 141 outpatients with active osteoarthritis of the knee or hip...

Hypersensitivity pneumonitis associated with co-proxamol (paracetamol + dextropropoxyphene) therapy. [1999.08]
A 61-year-old man developed hypersensitivity pneumonitis and skin rash in close association with taking co-proxamol. These problems occurred in spite of being treated with prednisolone 40 mg daily (20 mg daily at the time of presentation) for assumed cranial arteritis...

Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. [1997.12.13]
OBJECTIVE: To evaluate the comparative efficacy and tolerability of paracetamol-dextropropoxyphene combination and paracetamol through a systematic overview of randomised controlled trials... CONCLUSION: On the basis of data on analgesic efficacy and acute safety in both head to head and indirect comparisons, there is little objective evidence to support prescribing a combination of paracetamol and dextropropoxyphene in preference to paracetamol alone in moderate pain such as that after surgery.

more studies >>

Clinical Trials Related to Darvocet-N (Propoxyphene / Acetaminophen)

Lumbar Stenosis Outcomes Research II [Recruiting]
The primary objective of the proposed pilot study is to determine the efficacy of oxymorphone hydrochloride and propoxyphene/acetaminophen combination in prolonging the time to onset of pain and reducing the severity of pain associated with walking in patients with neurogenic intermittent claudication. The secondary objective is to examine the functional benefit of oxymorphone hydrochloride and propoxyphene/acetaminophen combination with respect to improvement in duration and distance of walking tolerance.

The proposed study will also provide the foundation for a treadmill-based methodology for assessing the analgesic efficacy of drugs for low back pain provoked by standing and walking associated with lumbar spinal stenosis.

more trials >>

PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Darvocet-N has an overall score of 6. The effectiveness score is 6 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
 

Darvocet-N review by 28 year old female patient

  Rating
Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   pain
Dosage & duration:   1-2 tablets every 4-6 hours taken 1 tablet every 6-8 hours for the period of 1-2 days
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   Treatment benefits were to address pain and discomfort. It was perscribed to me after I was in the hospital instead of Vicaden (spelling?), as Vicaden does not suite me well. The medication began working after about 45 minutes of taking it and (for me) lasted over 6 hours.
Side effects:   Treatment side effects for me were nausea and feeling unclear or 'loopy'. I found that if I took more than one pill within six hours, I became very nauseated. In addition, I would not have been able to function properly or drive a car comfortably because of the side effects with my clarity.
Comments:   The treatment was for pain and was taken by myself for a situation that could not have been allieviated by medical attention. I had an ovarian cyst rupture. My doctor and the ER told me there was really nothing for them to do other than wait for it to be reabsorbed. So, pain medication was my last resort. I took a few of these pills over two days to help alleviate my extreme pain.

See all reviews / ratings >>

Page last updated: 2009-11-05

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009